Faeth Therapeutics
Faeth Therapeutics is pioneering a new treatment paradigm in cancer therapy by harnessing metabolism and computational biology. Their mission is to use metabolism to beat cancer, focusing on improving and expanding drug targets through a data-driven, evidence-based approach that combines therapeutic targets and precision diets to enhance patient outcomes. They are actively involved in clinical trials and aim to transform cancer treatment with a focus on metabolic pathways, especially the PI3K/AKT/mTOR pathway.
Industries
Nr. of Employees
small (1-50)
Faeth Therapeutics
San Francisco, California, United States, North America
Patents
Products
Dual PI3Kα and mTORC1/2 inhibitor combination regimen (PI3K/mTOR pathway blockade)
Oral combination regimen designed to concurrently inhibit PI3Kα and mTORC1/2 signaling, developed for advanced endometrial cancer and evaluated with cytotoxic chemotherapy to increase tumor response.
Nonessential amino acid restriction medical food (NEAAR) for use with neoadjuvant therapy
Medical food implementing precise nonessential amino acid restriction evaluated as an adjunct to total neoadjuvant therapy for locally advanced rectal cancer.
Discovery platform for metabolic target identification and therapy design
Platform combining computational metabolic models and machine learning to identify metabolic drug targets and design combined drug-plus-diet regimens matched to tumor genotypes.
Dual PI3Kα and mTORC1/2 inhibitor combination regimen (PI3K/mTOR pathway blockade)
Oral combination regimen designed to concurrently inhibit PI3Kα and mTORC1/2 signaling, developed for advanced endometrial cancer and evaluated with cytotoxic chemotherapy to increase tumor response.
Nonessential amino acid restriction medical food (NEAAR) for use with neoadjuvant therapy
Medical food implementing precise nonessential amino acid restriction evaluated as an adjunct to total neoadjuvant therapy for locally advanced rectal cancer.
Discovery platform for metabolic target identification and therapy design
Platform combining computational metabolic models and machine learning to identify metabolic drug targets and design combined drug-plus-diet regimens matched to tumor genotypes.
Services
Design and execution of Phase I and early-phase combination therapy trials that incorporate precision dietary regimens alongside investigational drug combinations.
Mobile application and coaching services to support patient adherence to trial protocols and dietary programs.
Design and execution of Phase I and early-phase combination therapy trials that incorporate precision dietary regimens alongside investigational drug combinations.
Mobile application and coaching services to support patient adherence to trial protocols and dietary programs.
Expertise Areas
- Clinical trial management (early-phase oncology)
- Precision oncology and genotype-guided therapy
- Cancer metabolism and metabolic target discovery
- Preclinical cancer model evaluation (xenografts)
Key Technologies
- Machine learning for biological network modeling
- Computational metabolic network modeling
- Genotype-treatment matching platforms
- Preclinical xenograft tumor models